Scientific Director
Boehringer-Ingelheim

• 17 years of pharma industry experience at Boehringer Ingelheim
• Heading Structural Research Oncology Research in Vienna. Responsible for the following labs: Protein Science, Protein Crystallography, NMR & Analytics, Computational Chemistry, CryoEM
• Focus on “undruggable” cancer targets
• Responsibility for early project portfolio with respect to Enablement and Hit finding initiatives incl. FBS

Dr Stacey Southall, Director of Biophysics at Sosei Heptares Current research interests are GPCR drug discovery, primarily the contribution of biophysical and structural data to SBDD. Her team provides biophysical data such as SPR and MS to support a variety of internal and collaborative GPCR drug discovery programs. They also form the cryo-EM arm of the Sosei Heptares structural biology platform, complementing our X-ray crystallography capabilities and enabling SBDD. She completed her PhD in Biochemistry at University of Cambridge and followed this with post-doctoral positions at UEA, Institute of Cancer Research and EMBL-Hamburg prior to joining Sosei Heptares in 2014.